|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
February 2006FeaturesCover Story Biologics and Benefit Design: What’s New For '06?With the focus this year on Part D and with a number of biologic breakthroughs not yet on the market, payers only tinkered with their biopharma management strategies in ’06. New plan designs move more products to the pharmacy benefit and make greater use of HSAs. Regulatory CMS’ CAP Program: Worthy of Applause – Or Full of Flaws?Proposed changes to the drug acquisition program haven’t
quite mollified vendors and physicians who say they are
left on the hook. If you’re a health plan, this bears watching. Clinical Imaging Cancer Gene Activity in Patients From Outside the BodyResearchers in Philadelphia inject a nuclear medicine gene probe into patients, then use scanning techniques to see if active cancer genes light up. Diagnostics Storming the Molecular Diagnostic IP FortressHow companies exercise their patent rights affects patients’ access to medical tests, and maybe the future of medical test development, too. Business Biotechnology Innovations in Developing NationsWise use of local resources and an R&D focus on regional health concerns have given developing countries an edge in a competitive biotech market. DepartmentsOpeners Mighty Mouse
Michael D. Dalzell Editorial Really Smoking!David B. Nash, MD, MBA, on smoking-hot uses of the tobacco settlement. Washington Watch FDA Spades Field for Personalized MedicineNew FDA commissioner could lead industry closer to personalized medicine. Diagnostics and Devices Crawling Through the Millennia: Maggots and Leeches Come Full CircleMaggots and leeches? Oh, my! DrugTrack Approvals, FDA Actions, Clinical Trials
Bob Carlson Biotech Business Lack of Intellectual Property Protection Worldwide Threatens U.S. BiotechsIntellectual property threatened. Corporate Spotlight I.M.I.D. Spurs Innovations, Tough Payer QuestionsNew understanding of immunodeficiencies has yielded effective biologic therapies. The utility of these therapies changes the face of formulary decision making. Trends Intravenous Drugs May Be Losing Favor
Katherine T. Adams |
|||||